BR0215392A - Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas - Google Patents

Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas

Info

Publication number
BR0215392A
BR0215392A BR0215392-0A BR0215392A BR0215392A BR 0215392 A BR0215392 A BR 0215392A BR 0215392 A BR0215392 A BR 0215392A BR 0215392 A BR0215392 A BR 0215392A
Authority
BR
Brazil
Prior art keywords
inhibitor
pharmaceutical compositions
well
multifunctional
adenosine absorption
Prior art date
Application number
BR0215392-0A
Other languages
English (en)
Inventor
Yongge Liu
Bing Sun
Masuhiro Yoshitake
Jun-Ichi Kambayashi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR0215392A publication Critical patent/BR0215392A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS COMPREENDENDO UM INIBIDOR DE FOSFODIESTERASE MULTIFUNCIONAL E UM INIBIDOR DE ABSORçãO DE ADENOSINA, BEM COMO USO DAS MESMAS". A presente invenção refere-se a composições farmacêuticas compreendendo pelo menos um inibidor de fosfolipídeo esterase multifuncional (MPDEI) e pelo menos um inibidor de absorção de adenosina. A presente invenção também refere-se a composições compreendendo cilostazol e dipiridamol e seu uso.
BR0215392-0A 2001-12-27 2002-12-26 Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas BR0215392A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34236701P 2001-12-27 2001-12-27
US41254602P 2002-09-23 2002-09-23
PCT/US2002/041531 WO2003057222A1 (en) 2001-12-27 2002-12-26 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor

Publications (1)

Publication Number Publication Date
BR0215392A true BR0215392A (pt) 2004-12-07

Family

ID=26992976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215392-0A BR0215392A (pt) 2001-12-27 2002-12-26 Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas

Country Status (15)

Country Link
US (3) US20050165030A1 (pt)
EP (1) EP1461039B1 (pt)
JP (1) JP2005517680A (pt)
KR (1) KR20040083072A (pt)
CN (1) CN1607952A (pt)
AR (1) AR038091A1 (pt)
AU (1) AU2002360798A1 (pt)
BR (1) BR0215392A (pt)
CA (1) CA2471846A1 (pt)
DK (1) DK1461039T3 (pt)
ES (1) ES2525418T3 (pt)
MX (1) MXPA04006275A (pt)
PT (1) PT1461039E (pt)
TW (1) TW200301135A (pt)
WO (1) WO2003057222A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP2008545808A (ja) * 2005-05-23 2008-12-18 エラン・ファルマ・インターナショナル・リミテッド 血小板凝集阻害薬を含むナノ粒子状および制御放出組成物
US7811549B2 (en) 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
US20090042849A1 (en) * 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
WO2008076841A1 (en) * 2006-12-14 2008-06-26 Biokey, Inc. Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
WO2008143361A1 (en) * 2007-05-22 2008-11-27 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
US20090185973A1 (en) * 2008-01-22 2009-07-23 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
PL2448938T3 (pl) 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
US20110092456A1 (en) * 2009-10-19 2011-04-21 Yochai Birnbaum Methods of increasing cAMP levels and uses thereof
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102131612B1 (ko) 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP7036670B2 (ja) * 2018-05-31 2022-03-15 アークレイ株式会社 血液中の稀少細胞検査、該検査ための血液処理方法及び採血管
JP7332489B2 (ja) * 2019-01-28 2023-08-23 サントリーホールディングス株式会社 ホスホジエステラーゼ３阻害用組成物及び血小板凝集抑制用組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CN1658903A (zh) * 2001-01-26 2005-08-24 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与血液调节剂的组合

Also Published As

Publication number Publication date
CN1607952A (zh) 2005-04-20
TW200301135A (en) 2003-07-01
CA2471846A1 (en) 2003-07-17
KR20040083072A (ko) 2004-09-30
DK1461039T3 (en) 2015-01-12
ES2525418T3 (es) 2014-12-22
EP1461039A1 (en) 2004-09-29
WO2003057222A1 (en) 2003-07-17
EP1461039B1 (en) 2014-10-22
US20080200484A1 (en) 2008-08-21
PT1461039E (pt) 2014-12-12
US20100184784A1 (en) 2010-07-22
AU2002360798A1 (en) 2003-07-24
JP2005517680A (ja) 2005-06-16
US20050165030A1 (en) 2005-07-28
AR038091A1 (es) 2004-12-29
MXPA04006275A (es) 2004-10-04

Similar Documents

Publication Publication Date Title
BR0215392A (pt) Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas
BRPI9907866B8 (pt) composição farmacêutica, bem como seu uso
BRPI0413922A (pt) xantinas de 8-heteroarila substituìda
PT911333E (pt) Derivados de pirazolo¬4,3-d|pirimidina e composicoes farmaceuticas que os contenham
ATE242783T1 (de) Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
BRPI0317545A2 (pt) "composições de poli-hema de baixa polidispersão"
NO20032889L (no) Quinuklidin-karbamat-derivater samt medisinske sammensetninger omfattende slike
BR9915518A (pt) Combinações de substâncias ativas fungicidas
BR0013081A (pt) Pirimidino-2,4,6-trionas inibidoras de metaloproteinases
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
DE60209785D1 (de) Gipszusammensetzung mit verbesserter deformationsstabilität
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
DE60220567D1 (de) Fahrzeug- Vorderwagenaufbau
BR0201869B1 (pt) composições de pigmentos com dispersantes de copolìmeros em bloco modificados, bem como seu uso.
ECSP034874A (es) Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
BRPI0411013A (pt) implante para uso na fusão de estruturas ósseas adjacentes, método de tratar um organismo para promover fusão de estruturas ósseas adjacentes e sistema para uso na fusão de estruturas ósseas adjacentes
SE0001899D0 (sv) New compounds
ECSP014105A (es) COMPUESTOS DE PIRROLO [2,3-d] PIRIMIDINA
PT1280813E (pt) Analogos de nucleosidos de pirimidina antivirais
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
BR0209440A (pt) Sulfonamidas
PT1265612E (pt) Composicao farmaceutica compreendendo pemetrexed conjuntamente com monotioglicerol l- cisteina ou acido tioglicolico
BR0213019B1 (pt) formulaÇço para uso na neutralizaÇço de pelo menos uma substÂncias tàxica.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]